Benitec Biopharma initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Raghuram Selvaraju initiated coverage of Benitec Biopharma (BNTC) with a Buy rating and $28 price target Benitec is a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference platform, the analyst tells investors in a research note. The firm says initial clinical findings “appear encouraging, with strong mechanistic rationale for therapeutic impact.”